With the purchase of Organon & Co., billionaire Dilip Shanghvi's Sun Pharmaceutical Industries' annual revenue will more than double to $12.4 billion and make it one of the world’s top 25 drugmakers.

With the purchase of Organon & Co., billionaire Dilip Shanghvi's Sun Pharmaceutical Industries' annual revenue will more than double to $12.4 billion and make it one of the…

To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion.